Archive for the ‘Hospital Clínic de Barcelona’ Category

Wednesday January 24th, 2018

Fourth call of the PhD4MD biomedical research training programme for medical doctors

The Centre for Genomic Regulation (CRG), the August Pi i Sunyer Biomedical Research Institute  (IDIBAPS), the Institute for Research in Biomedicine (IRB Barcelona), and the Vall d’Hebron Research Institute (VHIR) have launched the fourth call of the training programme “PhD for Medical Doctors – PhD4MD”. Read the rest of this entry »

Tuesday January 23rd, 2018

Researchers identify a protein that keeps metastatic breast cancer cells dormant

The time needed for breast cancer metastases (secondary lesions caused by cells that have escaped from the original tumour) to develop varies between patients, and little is known about the mechanisms that govern latency (the dormant state of cells that have already spread through the body). A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light on the molecular basis underlying how the expression of certain genes facilitates the spread of metastatic lesions. Dr. Aleix Prat, Head of the Clinical Oncology Department at Hospital Clínic and of the Translational genomics and targeted therapeutics in solid tumors research team at IDIBAPS, has participated in this study. Read the rest of this entry »

Friday December 29th, 2017

El Dr. Ricard Cervera, Presidente de Honor del 5th Latin American Congress of Autoimmunity


Los pasados 26 al 29 de noviembre tuvo lugar en Cancún (Mèxic) el 5th Latin American Congress of Autoimmunity, el encuentro más importante de los especialistas de los laboratorios de inmunidad y de los clínicos de las principales especializades relacionadas con las enfermedades autoinmunes. Este año, el congreso ha contado con el Dr. Ricard Cervera, Jefe del Servicio de Enfermedades Autoinmunes (ICMiD), como Presidente de Honor, junto con el Dr. Yehuda Schoenfeld de Israel.

Read the rest of this entry »

Comments Closed
Saturday December 16th, 2017

A new combination of antibiotics allows treating 60% of hospital-acquired pneumonia

A study published in the journal The Lancet Infectious Diseases shows the ability of a new antibiotic (ceftazimida-avibactam) to treat hospital-acquired pneumonia, including ventilation-associated pneumonia. It has similar efficacy to one of the most used type of antibiotics in the treatment of this infection, carbapenems, but has the advantage of overcoming problems derived from its administration, such as the resistance of certain bacteria. Dr. Antoni Torres, Head of the Respiratory Intensive Surveillance Unit (UVIR) of the Hospital Clínic and head of the IDIBAPS team on Applied research in infectious respiratory diseases, critically ill patients and lung cancer, is the principal investigator of the study and first author of the article. Read the rest of this entry »

Comments Closed

Categories

Posted in:

Monday June 26th, 2017

Jaume Bosch coordinates the guidance on the management of portal hypertensive bleeding in cirrhosis published in Hepatology

Hepatology, the official journal of the American Association for the Study of Liver Diseases, has published a practice guidance entitled Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management. The study is coordinated by Dr. Jaume Bosch, hepatologist at Hospital Clínic and head of the research team Liver hemodynamics and portal hypertension at IDIBAPS. The other three authors, Dr. Juan G. Abraldes and Dr. Annalisa Berzigotti, are former IDIBAPS researchers, and Dr. Guadalupe Garcia-Tsao made a stay at this institution. The main newness of this guidance is the adaptation of the treatments to the various phases of cirrhosis. Read the rest of this entry »

Comments Closed
Monday June 12th, 2017

Aleix Prat, named Board Member of the Breast International Group

Dr. Aleix Prat, Head of the Clinical Oncology Department at Hospital Clínic and of the Translational genomics and targeted therapeutics in solid tumors research team at IDIBAPS, has been named member of the Executive Board of the Breast International Group (BIG). The BIG is an international non-profit organisation that includes more than 56 cooperative groups from around the world, more than 10,000 experts and it is linked to more than 3,000 hospitals. Its main goal is to promote clinical and translational research in breast cancer. The appointment, which represents a recognition to his professional career in this field, took place during the annual meeting of the American Society of Clinical Oncology (ASCO) held in June 2-6 in Chicago. Read the rest of this entry »

Comments Closed
Page 1 of 5712345...Last »